Given that MYBL2 High patients have significantly poorer outcomes (Figure 2, Tables 1, 2), we explored the cytotoxic efficacy of small molecule CHK1 inhibitors in MYBL2 High lung adenocarcinoma cells. This evidence concerns the gene MYBL2 and lung adenocarcinoma.